探索胃癌中的m6A修饰:从分子机制到临床应用
Penghui Li1, Xiangjie Fang2, Di Huang3
1Department of Gastrointestinal Surgery, The First Affiliated Hospital, College of Clinical Medicine, Henan University of Science and Technology, Luoyang, 471000, Henan, China. lph0819@163.com.
European journal of medical research
|February 12, 2025
概括
在胃癌 (GC) 进展和治疗耐药性方面,N6-甲基氨酸 (m6A) 修改至关重要. 了解m6A调节器为改善GC诊断和治疗提供了潜力.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
背景情况:
- N6-甲基氨酸 (m6A) 修饰在各种生物过程中发挥着关键作用,特别是癌症.
- 在胃癌 (GC) 中,m6A 修改显著参与瘤进展,转移和对治疗的抵抗.
研究的目的:
- 提供一个全面的审查m6A修改在GC的作用.
- 强调m6A在GC中的分子机制,临床意义和翻译应用.
主要方法:
- 在胃癌中对m6A修饰的文献综述.
- 分析m6A调节剂的表达及其与临床结果的关联.
- 关于m6A对瘤生长相关的细胞功能的影响的总结.
主要成果:
- 在GC中观察到m6A调节者的差异表达 (如METTL3,WTAP之类的写字器;如FTO,ALKBH5之类的脱甲基酶).
- 作者的高表达与预后不佳相关,而METTL14的低表达和脱甲基酶的高表达与临床结果有关.
- m6A调节剂影响GC中的增殖,入侵,迁移,糖解和化疗耐药性.
结论:
- m6A修饰模式和调节器表达特征对GC诊断和治疗非常有价值.
- 准m6A修改为GC的新诊断和治疗策略提供了潜在的潜力.
- 对m6A机制的进一步研究可以提高胃癌的临床管理.
相关概念视频
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K
Adaptive Mechanisms in Cancer Cells
5.7K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.7K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Metastasis
5.5K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
5.5K
Treatment Resistant Cancers
3.2K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.2K


